Breast Cancer Clinical Trials in Tennessee

Showing 521-540 of 604 trials

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

NCT00193180

This trial evaluates the novel combination of docetaxel with imatinib as first or second line therapy in advanced breast cancer with the aim of achieving higher effectiveness and potentially reducing side effects.

Breast Cancer

SCRI Development Innovations, LLC37 participantsStarted May 2005

Gainesville, Georgia, United States • Louisville, Kentucky, United States • Baton Rouge, Louisiana, United States +3 more locations

COMPLETEDPhase 129 miles

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00574366

RATIONALE: Erlotinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving erlotinib together with everolimus and to see how well it works in treating patients with metastatic breast cancer.

Breast Cancer

Vanderbilt-Ingram Cancer Center14 participantsStarted Dec 2005

Nashville, Tennessee, United States • Nashville, Tennessee, United States • Nashville, Tennessee, United States

COMPLETEDNA29 miles

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

NCT01048099

This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2 overexpression/activation by the PRO Onc Assay.

Breast Cancer

SCRI Development Innovations, LLC283 participantsStarted Jan 2011

Fort Myers, Florida, United States • St. Petersburg, Florida, United States • Cincinnati, Ohio, United States +4 more locations

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Breast Cancer Trials in Other Cities

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

ICI 182780 in Treating Women With Metastatic Breast Cancer

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Other Conditions in Tennessee